🟢 Definium Therapeutics is trading 4.1% up today following positive Phase 3 trial results and a $700M capital raise

Definium Therapeutics is trading at $47.17 (+4.1%), extending its recent strength after reporting positive clinical data and completing a significant equity raise.

• The company's Phase 3 Emerge trial of DT120 met all primary and key secondary endpoints in major depressive disorder.
• Definium recently completed an upsized public offering of over $700 million, significantly strengthening its balance sheet.
• The combination of clinical success and robust capital position continues to drive bullish sentiment among investors.